Atossa Therapeutics Inc (ATOS)
$1.50
0.01 (0.67%)
ATOS Stock Quote Delayed 30 Minutes
ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023
ATOS stock results show that Atossa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
188.68M
PE Ratio
-37.50
EPS
-0.04
Volume (Avg. Vol.)
2.34M
Day's Range
$1.48 - $1.60
52-Week Range
$0.59 - $2.31
Dividend & Yield
N/A (N/A)
ATOS Stock Predictions, Articles, and Atossa Therapeutics Inc News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for a dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning!
3 Best Penny Stocks Under $1 to Buy in April
By their very nature, the best penny stocks under $1 are a huge gamble with potentially huge returns for speculative investors.
ATOS Stock Holders Should Mark Their Calendars for Oct. 7
Today, investors in Atossa Pharmaceuticals and ATOS stock appear to be cheering a delayed shareholder vote on a stock issuance proposal.
Atossa Therapeutics Stock Lost Its Covid Mojo, and Its Pipeline Fails To Impress
Atossa’s COVID-19 treatment is too little too late and I am concerned about the market size for Endoxiden. ATOS stock should not have a $448 million market cap.
Atossa Therapeutics Has a Steep Climb Ahead of It
Atossa Therapeutics is popular with the Reddit crowd. However, ATOS stock doesn’t make the top 25 on the platform. Should you buy it anyway?
As its Meme Status Has Come and Gone, Skip Out on Atossa Therapeutics Stock
So, overvalued, with low squeeze odds, what's the best move with ATOS stock? Sell or avoid, before dilution and other factors push it back down to its pre-hype price levels of around $1 per share.
Don’t Give In to Temptation in Atossa Therapeutics
Atossa Therapeutics has made a pivot to assist in the battle to fight Covid-19. But it seems that investors in ATOS stock are finding this to be a message they've already heard.
With Zero Revenue, I Can’t Get Excited About Atossa
ATOS stock surged briefly in 2021 based on several catalysts, but none of them right now is supportive of its current price and valuation.
The Bear Case for Atossa Therapeutics Makes More Sense at This Time
Investors have become wary of the risks surrounding Atossa's pipeline. That caution will continue pulling down ATOS stock
Investors Should Avoid High-Risk Atossa Therapeutics
Given the early stages of Atossa's clinical trials, ATOS stock is too risky to get involved with at this point.
ATOS Stock: The Big News That Has Atossa Therapeutics Plunging 20% Today
ATOS stock is on its way down today. As the biotech company announces a special shareholder meeting, holders worry about stock dilution.
Wait for Atossa Therapeutics Stock to Slide Further Before Buying
The potential with its breast cancer and Covid-19 treatment candidates notwithstanding, don't fight the trend with ATOS stock.
